Article
Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC.
BMC medicine - 7 Oct 2021
Sun Yiting, Duan Jianchun, Fang Wenfeng, Wang Zhijie, Du Xinyang, Wang Xin, Li Chengcheng, Cai Shangli, Zhao Jie, Li Sini, Zhang Li, Bai Hua, Wang Jie
Abstract excerpt
BACKGROUND: With the revolutionary progress of immune checkpoint inhibitors (ICIs) achieved in non-small cell lung cancers (NSCLC), identifying patients benefiting from ICIs becomes critical and urgent. The associations of genomic alterations in protein tyrosine phosphatase receptor-type (PTPRs) and ICIs responses are unknown. METHODS: Whole-exome sequencing (WES) of 73 advanced NSCLC tumors sampled before...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.